Genome sequencing co Ultima Genomics raises $600m
Genome sequencing company Ultima Genomics has arrive out of stealth and declared $600 million in financing. Launched in 2016 by its Israeli CEO Gilad Almogy, the company has 350 staff members including 50 in Israel at advancement facilities in Rehovot and Hod Hasharon, and remarkably has managed to avoid any leaks of data from its staff, buyers and development centers.

The company has now exposed that it has created a sequencing device, which it promises, backed up by study established to be revealed in main scientific periodicals, will allow genome sequencing for $100, in comparison with the $500-600 it fees applying its rival Illumina (Nasdaq: ILMN). In addition, Ultima Genomics promises that its genomic sequencing is a lot quicker and deeper – in other words and phrases, it supplies extra data about the genome, extra promptly.

The rewards of these improvements, which are authorized by way of patents that the firm has not but revealed, are largely in two directions. Via this technologies, the company estimates and hopes, it will be feasible to accomplish genome sequencing even down to single cells, and as a result diagnose ailments even previously than at present, mostly most cancers. In addition, sequencing that is more cost-effective, speedier and richer in details, will permit a lot faster progress in tasks that compare the genetics of the true morbidity of significant numbers of individuals, in buy to map the genes involved in a variety of ailments.

Sources at Ultima Genomics say that the reason for the secrecy more than the a long time was the need to access the point where by the company could establish its merchandise, ahead of making any bulletins. The corporation also desired not to stir up its rivals, predominantly Illumina.

Ultima Genomics CEO and founder Gilad Almogy is a graduate of the IDF’s Talpiot science and leadership software. Almogy is now resident in the US. He was a senior vice president at Used Elements just before founding photo voltaic strength company Cogenra Solar in 2009, which was acquired by SunPower in 2015. In late 2016, Almogy established Ultima.

Almogy mentioned, “DNA is nature’s storage media and the instruction set for every single residing organism, nonetheless with existing technologies, we are unable to obtain that data at the scale essential to genuinely fully grasp complicated biology. Our architecture is supposed for radical scaling, and the $100 genome is merely the first example of what it can supply. We are fully commited to continually drive down the price tag of genomic details till it is routinely used in each and every element of the health care procedure.”




Linked Content articles




aMoon closes $660m Israeli overall health-tech VC fund







Ultima Genomics CSO Doron Lipson extra, “Experts and clinicians consistently make tradeoffs between the breadth, depth, and frequency of genomic information they acquire. By overcoming the limits of conventional upcoming-generation sequencing systems, scientists can now style experiments and medical assays that have been beforehand impossible.”

One of the very first traders in Ultima Genomics was Israeli billionaire and Look at Stage founder Marius Nacht, who is also a graduate of the IDF’s Talpiot plan. Nqcht started the aMoon healthtech and life science financial commitment fund, initially investing his personal assets before starting to be an impartial fund, which in recent many years lifted a $750 million development fund. aMoon has also invested in Ultima Genomics.

Other buyers in Ultima Genomics involve D1 Cash, Andreessen Horowitz, Typical Atlantic, Khosla Ventures, Lightspeed, Playground World, and Founders Fund.

Whole disclosure: Marius Nacht is the previous life spouse of Anat Agmon, aspect of the managing shareholders in “Globes.” They are included in a personalized and financial dispute

Printed by Globes, Israel organization information – en.globes.co.il – on June 2, 2022.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2022.


